Experimental Hepatitis B Drug Delivers Functional Cure In 20 Percent Of Patients
Researchers presented Phase 3-style data on May 28, 2026 in Barcelona showing the experimental hepatitis B drug bepirovirsen produced an off-treatment functional cure in about 20% of patients, a result now under fast-track FDA review.[1]
The analysis included 1,838 patients and found roughly 20% of those receiving bepirovirsen plus standard antiviral pills had undetectable virus six months after stopping all treatment, versus 0% on placebo.[1] The findings were presented at a scientific meeting in Barcelona and published May 28 in the New England Journal of Medicine.[1] The FDA is reviewing bepirovirsen on a fast-track timetable with a regulatory decision expected in October 2026.[1]
Phase 3-style studies are designed to test whether a therapy can produce durable viral suppression when patients stop taking medicines. Here, "functional cure" meant sustained undetectable viral levels six months after all treatments stopped.
Approval could offer a new option for people with chronic hepatitis B, but most patients in the trial did not reach the off-treatment threshold and longer follow-up and safety data will be needed before the new drug changes standard care.
Show source details & analysis (1 source)
📌 Key Facts
- On May 28, 2026, researchers reported Phase 3-style data on bepirovirsen in 1,838 hepatitis B patients.
- About 20% of patients receiving bepirovirsen plus standard pills had undetectable virus six months after stopping all treatment, versus 0% on placebo.
- The findings were presented at a Barcelona scientific meeting and published May 28, 2026 in the New England Journal of Medicine.
- The FDA is reviewing bepirovirsen on a fast-track basis, with a regulatory decision expected in October 2026.
📰 Source Timeline (1)
Follow how coverage of this story developed over time